Skip to main content
News

Dr Carlos Wesley joins HairClone as newest Banking Associate

By March 18, 2024No Comments

HairClone is proud to welcome our newest Banking Associate, Dr. Carlos K. Wesley, M.D., who joins us from New York City. His facility, fully equipped with two surgical suites, has received The National Quality Approval of The Joint Commission, highlighting the highest level of care and safety with patients.

Dr. Wesley’s clinic, located on Fifth Avenue New York City, offers a range of treatments, including Follicular Unit Extraction (FUE), Follicular Unit Transplantation (FUT), and Scarless Surgery. In additional to practicing medicine, Dr. Wesley is the Founder and CEO of the biomedical technology company Pilofocus, which is dedicated to scarless surgical hair treatments.

Dr. Wesley received his medical degree from Yale University School of Medicine, and has furthered the hair restoration industry and surgical field through publications and international lecturers. Dr Wesley is renowned in the hair transplantation world, in which he specialises in the medical and surgical treatment of men and women’s hair loss.

As a leading site for the latest scientific advances, Dr Wesley’s clinic now offers patients the opportunity to cryopreserve follicles with HairClone’s follicle banking service. This process involves surgically extracting and freezing 100-120 hair follicles; a process that stops biological action and inhibits cellular ageing.

Among the numerous cells found within whole hair follicles are the dermal papilla cells. These cells have great potential for regenerative therapies, including use in HairClone’s cell therapy that is currently undergoing pre-clinical validation. This personalised cell therapy involves extracting and multiplying dermal papilla cells from the cryopreserved hair follicles, and injecting them into miniaturising regions of the scalp with the aim of rebuilding and rejuvenating hair.

We look forward to working with Dr Wesley and allowing more patients to access this service.